Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | CRYZ | Q08257 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclophosphamide Anhydrous SCHEMBL28088100 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL7304 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4346 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5328735 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL1285823 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL20542636 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4994883 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5802618 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL6071 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5436000 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329878-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | Dnatrix, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| WO-2022232176-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | DNATRIX, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| EP-4648776-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF TYPE 1 DIABETES | Pfizer Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12433905-B2 | Stable oral composition of cyclophosphamide | INTAS PHARMACEUTICALS LTD. (IN) | 2025-10-07 | — | — | US | disclosed |
| CN-119909198-A | Alpha-cyperus ketone bionic nano preparation and preparation method and application thereof | 宁夏医科大学总医院 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024229600-A1 | SOLUBLE BIOMOLECULAR GLASS AND USE THEREOF | 中国科学院过程工程研究所 | 2024-11-14 | — | — | WO | disclosed |
| EP-4440554-A1 | A PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION | Sava Healthcare Ltd (IN) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024150110-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF TYPE 1 DIABETES | PFIZER INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4329878-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | Dnatrix, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230310468-A1 | Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids | SANDOZ AG (CH) | 2023-10-05 | — | — | US | disclosed |
| US-20230310468-A1 | Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids | SANDOZ AG (CH) | 2023-10-05 | — | — | US | disclosed |
| CN-116322766-A | anti-CD 2 antibodies | 泽拉里翁马耳他有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023099968-A1 | A PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION | SAVA HEALTHCARE LTD (IN) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022232176-A1 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | DNATRIX, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220265688-A1 | STABLE ORAL COMPOSITION OF CYCLOPHOSPHAMIDE | INTAS PHARMACEUTICALS LTD. (IN) | 2022-08-25 | — | — | US | disclosed |
| EP-4003390-A1 | METHOD FOR TREATING SOLID TUMORS | Breakbio Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3996685-A1 | STABLE ORAL COMPOSITION OF CYCLOPHOSPHAMIDE | Intas Pharmaceuticals Ltd. (IN) | 2022-05-18 | — | — | EP | disclosed |
| WO-2008076257-A2 | TREATING CANCER WITH ANTI-IGFLR ANTIBODY 19D12 = SCH 717454 | SCHERING CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310468-A1 | Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids | CXCR3, CCR3, FCGRT | NPSR1 4110/4885KDM4E 1668/4885ALOX15 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.